Advertisement
UK markets open in 2 hours 24 minutes
  • NIKKEI 225

    38,391.63
    -841.17 (-2.14%)
     
  • HANG SENG

    16,279.56
    -320.90 (-1.93%)
     
  • CRUDE OIL

    85.95
    +0.54 (+0.63%)
     
  • GOLD FUTURES

    2,402.80
    +19.80 (+0.83%)
     
  • DOW

    37,735.11
    -248.13 (-0.65%)
     
  • Bitcoin GBP

    50,408.78
    -1,833.62 (-3.51%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,885.02
    -290.08 (-1.79%)
     
  • UK FTSE All Share

    4,338.90
    -14.76 (-0.34%)
     

Analysts’ Ratings for Radius Health and Its Peers in January

Analysts’ Ratings for Radius Health and Its Peers in January

Radius Health (RDUS) is a biopharmaceutical company that has recently turned into a commercial stage healthcare company. Of the seven analysts covering Radius Health in January 2018, three have given the stock “buy” or higher ratings, while four have given it “hold” ratings. The mean rating for the stock is 2.43, and it has a target price of $47.5.